PD-1/PD-L1 Pathway in Breast Cancer

被引：134

作者：

Schuetz, Florian ^{[1
]}

Stefanovic, Stefan ^{[1
]}

Mayer, Luisa ^{[1
]}

von Au, Alexandra ^{[1
]}

Domschke, Christoph ^{[1
]}

Sohn, Christof ^{[1
]}

机构：

[1] Univ Frauenklin Heidelberg, Interdisziplinares Brustzentrum, Neuenheimer Feld 440, D-69120 Heidelberg, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷 / 05期

关键词：

PD1/PD-L1; Breast cancer; Immune checkpoints; Immunotherapy; T-CELL-ACTIVATION; IMMUNE CHECKPOINT BLOCKADE; HUMAN OVARIAN-CANCER; INDUCED EXPRESSION; PD-1; LYMPHOCYTES; TOLERANCE; DISEASE; MICE; GENE;

D O I：

10.1159/000464353

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The programmed cell death-1 receptor (PD-1) is an immune checkpoint inhibitor which is expressed on the surface of immune effector cells. It is activated mainly by PD-L1 which can be expressed by all human cells. The PD-1/PD-L1 pathway plays a subtle role in maintaining peripheral T-lymphocyte tolerance and regulating inflammation. In cancer, the expression of PD-L1 seems to be one of the major immune escape mechanisms. Many studies have shown efficacy of blocking PD-1 or PD-L1 with specific antibodies like pembrolizumab or atezulizumab. In breast cancer, potential response was demonstrated in metastatic triple-negative breast cancers. (C) 2017 S. Karger GmbH, Freiburg

引用

页码：294 / 297

页数：4

共 50 条

[1] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
Monneur, Audrey
Goncalves, Anthony
Bertucci, Francois
[J]. BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
[2] Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
Bai, Jie
Gao, Zhitao
Li, Xiang
Dong, Liang
Han, Weidong
Nie, Jing
[J]. ONCOTARGET, 2017, 8 (66) : 110693 - 110707
[3] Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway
Barclay, Jonathan
Creswell, Joanne
Leon, Juan
[J]. ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (04): : 393 - 399
[4] PD-1/PD-L1 pathway: current researches in cancer
Han, Yanyan
Liu, Dandan
Li, Lianhong
[J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (03): : 727 - 742
[5] Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression
Saito, Hiroaki
Kono, Yusuke
Murakami, Yuki
Shishido, Yuji
Kuroda, Hirohiko
Matsunaga, Tomoyuki
Fukumoto, Yoji
Osaki, Tomohiro
Ashida, Keigo
Fujiwara, Yoshiyuki
[J]. ANTICANCER RESEARCH, 2018, 38 (01) : 107 - 112
[6] A snapshot of the PD-1/PD-L1 pathway
Ghosh, Chinmoy
Luong, Gary
Sun, Yue
[J]. JOURNAL OF CANCER, 2021, 12 (09): : 2735 - 2746
[7] Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Ohaegbulam, Kim C.
Assal, Amer
Lazar-Molnar, Eszter
Yao, Yu
Zang, Xingxing
[J]. TRENDS IN MOLECULAR MEDICINE, 2015, 21 (01) : 24 - 33
[8] PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
Velho, Pedro Isaacsson
Antonarakis, Emmanuel S.
[J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (05) : 475 - 486
[9] Regulation of PD-1/PD-L1 Pathway in Cancer by Noncoding RNAs
Ding, Lei
Lu, Shengdi
Li, Yanli
[J]. PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (02) : 651 - 663
[10] Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond
Ai, Luoyan
Xu, Antao
Xu, Jie
[J]. REGULATION OF CANCER IMMUNE CHECKPOINTS: MOLECULAR AND CELLULAR MECHANISMS AND THERAPY, 2020, 1248 : 33 - 59

← 1 2 3 4 5 →